Therefore, we conclude that the combination of BRAF V600 and HSP90 inhibition represents a novel and likely effective therapeutic option for patients with thyroid cancer, especially those that have failed previous treatments. This evidence concerns the gene BRAF and thyroid gland carcinoma.